Major Depressive Disorder Clinical Trials in Los Angeles, California

9 studies are recruiting for major depressive disorder in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Pain and Major Depressive Disorder

   This study will examine the effects of brain stimulation on pain symptoms associated with Major depressive disorder. This study will enroll 54 Subjects. Study subjects will be asked to complete surveys about their mood and well-being, 2 blood draws, 2 MRIs, 3 electroencephalograms, and receive 30 t…

   Stage

   Not phased

   Ages

   18 to 75

   Site

   UCLA Semel Institute, Los Angeles, California

   Run by

   University of California, Los Angeles

   See if you can join NCT04556890 on ClinicalTrials.gov

2. NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Los Angeles, California

   Locations

   35 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06963021 on ClinicalTrials.gov

3. Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

   The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a l…

   Stage

   Phase 2

   Ages

   18 to 64

   Site

   CalNeuro Research Group, Los Angeles, California

   Locations

   34 in total

   Run by

   Syndeio Biosciences, Inc

   See if you can join NCT06547489 on ClinicalTrials.gov

4. A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

   X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   CalNeuro Research Group, Inc., Los Angeles, California

   Locations

   51 in total

   Run by

   Xenon Pharmaceuticals Inc.

   See if you can join NCT06775379 on ClinicalTrials.gov

5. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Los Angeles, California

   Locations

   106 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06966401 on ClinicalTrials.gov

6. Evaluating tDCS Brain-stimulation in Depression Using MRI

   Patients, physicians, and those who fund depression research are keenly interested in depression treatments that do not involve taking medications. One promising candidate treatment is transcranial direct current stimulation (tDCS), a low-cost technique that involves placing electrodes on specific …

   Stage

   Not phased

   Ages

   20 to 55

   Site

   University of California Los Angeles (UCLA), Los Angeles, California

   Run by

   University of California, Los Angeles

   See if you can join NCT05598034 on ClinicalTrials.gov

7. Regulation of Affect and Physiology in Depression

   Although treatments for depression are effective for many people, not everyone responds to treatment. This lack of treatment response could be due, in part, to the presence of multiple underlying causes of people's depression. This study aims to identify subtypes of depression, based on two factors…

   Stage

   Phase 2

   Ages

   18 to 27

   Site

   University of Southern California, Los Angeles, California

   Run by

   University of Southern California

   See if you can join NCT06345859 on ClinicalTrials.gov

8. In-patient SCC TMS

   The investigators are studying the feasibility, safety, and tolerability of administering accelerated repetitive Transcranial magnetic stimulation(a-rTMS) at frequencies other than standard 10 Hz for in-patient Subjects diagnosed with Major Depressive Disorder. Participants will be recruited from t…

   Stage

   Not phased

   Ages

   18 to 65

   Site

   UCLA TMS Service and Research Service, Los Angeles, California

   Run by

   University of California, Los Angeles

   See if you can join NCT05645575 on ClinicalTrials.gov

9. Study of ALTO-300 in MDD

   The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

   Stage

   Phase 2

   Ages

   18 to 70

   Site

   Site 209, Los Angeles, California

   Locations

   45 in total

   Run by

   Alto Neuroscience

   See if you can join NCT05922878 on ClinicalTrials.gov